Claim · 2026-02-26 · publication · Stated in source · Supported

Generate Biomedicines' IPO prospectus (26 February 2026) states that "Biology is an information science" and that DNA's encoding of function "in principle, makes biology programmable".

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Generate Biomedicines, Inc. IPO prospectus (424B4) → states provision → framing statement: "Biology is an information science."

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Generate Biomedicines, Inc. IPO prospectus (424B4)states provision ↓framing statement: "Biology is an information science."

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Provision: Statement · provision ID co-generate-information-science-2026
Date: 2026-02-26 · publication Records dated 2026 →

Scope and limitsA company's framing statement in an offering document; recorded as what the text says. It is not recorded as a text on a proposition.

The evidence 01

primary sourceSupports the claim

Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock

Generate Biomedicines, Inc. (filed with the US SEC) · 2026-02-26

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“Biology is an information science. DNA encodes biological function through the way its sequence determines the structure and activity of the molecules it produces, which, in principle, makes biology programmable.”

Location in source Prospectus summary, "Overview"

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Generate Biomedicines, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Generate Biomedicines, Inc. (filed with the US SEC), “Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock”, 2026-02-26.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (30 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.

Date. Prospectus date.

Record ID aib-co-generate-information-science-2026